PCSA Director Receives 100K RSUs and 300K Options with $0.198 Strike
Rhea-AI Filing Summary
Neal James R, a Director of Processa Pharmaceuticals, Inc. (PCSA), reported issuance of equity awards dated 10/01/2025. The Form 4 shows 100,000 Restricted Stock Units (RSUs) granted with a reported value of $0 and 300,000 stock options granted with a conversion/exercise price of $0.198. Following the reported transactions the reporting person beneficially owns 100,000 RSUs and 300,000 options, each held directly. The RSUs vest one-third on 10/01/2026 and then one-thirty-sixth monthly until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant, with the remainder vesting ratably over the next two years. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and dated 10/03/2025.
Positive
- Director alignment via 100,000 RSUs and 300,000 options awarded on 10/01/2025
- Clear vesting schedules: RSUs fully vest by 10/01/2028; options vest over three years
Negative
- None.
Insights
Director received time‑based equity: 100,000 RSUs and 300,000 options.
The filing documents standard, time‑based equity grants to a director on 10/01/2025. The RSUs convert to common shares following the disclosed vesting schedule ending 10/01/2028, and the options carry an exercise price of $0.198 with staged vesting over three years.
This shows a direct alignment of the reporting director with long‑term equity incentives; the Form 4 confirms direct beneficial ownership of the disclosed awards and the specific vesting timelines that govern when shares may be received.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 100,000 | $0.00 | -- |
| Grant/Award | Stock Options (Right to Buy) | 300,000 | $0.00 | -- |
Footnotes (1)
- Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.
